News Novo hopes hypoglycaemia data will boost Tresiba Lower severe hypo risk compared with Lantus - but no cardiac benefit.
News Amgen/UCB's osteoporosis drug hit by cardio risk Competitor to Amgen's Epogen also moves closer to market
News AZ’s Bydureon disappoints in diabetes outcomes trial Results give advantage to Boehringer/Lilly's Jardiance.
News AI-based Apple Watch app detects arrhythmia with 97% accurac... App also achieves 98% sensitivity and 90.2% specificity.
News Abbott earns CE mark for smartphone-enabled cardiac monitor Confirm Rx Insertable Cardiac Monitor transmits data to smartphone app.
News J&J looks to Actelion to boost sales after poor Q1 Johnson & Johnson is hoping its new acquisition Actelion will help stave off the effects of a price squeeze in the US, and a cheaper biosimilar of its bestseller, Remicade.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
